Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Application Filing Expected in FY2018 for Cancer Peptide Vaccine Originating from Kurume Univ.
May 30, 2016
- Kyorin to Exclusively Market MSD’s Desloratadine in Japan
May 27, 2016
- Astellas Grants Thunderbolt Pharma Rights for BAFF/APRIL Dual Antagonist Program
May 26, 2016
- Eisai Rolls Out AMPA Receptor Antagonist Fycompa
May 26, 2016
- AZ Launches Tagrisso for Treatment of NSCLC
May 26, 2016
- Shionogi’s Naldemedine Delivers Positive Results in Global PIII
May 25, 2016
- Hyperparathyroidism Drug Etelcalcetide Meets Primary Endpoint in Japan PIII: Ono
May 25, 2016
- Toyama Chemical Files Ozex for Mycoplasma Pneumoniae at Request of Academic Societies
May 25, 2016
- Bardoxolone Methyl Improves Renal Function in Japan PII: Kyowa Kirin
May 24, 2016
- PCSK9 Inhibitor Alirocumab Lowers LDL-C in Japanese Diabetes Patients: PIII Sub-Analysis
May 24, 2016
- Japan’s Top 3 Drug Makers Join Forces on Biomarker Research
May 24, 2016
- Repatha Shows Safety, Efficacy in Japanese Patients Regardless of Glycemic Status: Subanalysis Data
May 24, 2016
- Ozawa to Step Down as J-TEC CEO, Fujifilm’s Hiruma to Take Over
May 23, 2016
- Jiangsu Hengrui Medicine Eyes Launch of 2-3 Generics in Japan Every Year: CEO
May 23, 2016
- Generic Makers Enjoy Revenue Rises as Govt Tailwinds Continue: Jiho Tally
May 23, 2016
- Chugai, Osaka Univ. Clinch 10 Billion Yen Immunology Pact
May 20, 2016
- Ono Ties Up with Univ. of Tokyo Venture for Antibody Drug
May 19, 2016
- Suzuken Outstrips Medipal in Drug Wholesaling Biz on Hep C Boom: Jiho Tally
May 19, 2016
- Takecab Most Heavily Pitched Drug for 3 Consecutive Months: Anterio
May 18, 2016
- Harvoni Tops Japan Yearly Sales Ranking Only 7 Months after Launch: IMS
May 18, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…